Quarterly Report • Feb 3, 2022
Quarterly Report
Open in ViewerOpens in native device viewer
| Income Statement Borregaard Group Q4 2021 | ||||
|---|---|---|---|---|
| 1.10-31.12 | 1.1-31.12 | |||
| Amounts in NOK million | 2021 | 2020 | 2021 | 2020 |
| Operating revenues | 1 446 | 1 338 | 5 805 | 5 328 |
| Operating expenses | -1 183 | -1 075 | -4 433 | -4 196 |
| EBITDA | 263 | 263 | 1 372 | 1 132 |
| Depreciation property, plant and equipment | -106 | -110 | -416 | -443 |
| Amortisation intangible assets | -1 | -2 | -4 | -5 |
| Other income and expenses | 0 | -20 | 0 | -116 |
| Operating profit | 156 | 131 | 952 | 568 |
| Financial items, net | -24 | -12 | -79 | -72 |
| Profit before taxes | 132 | 119 | 873 | 496 |
| Income tax expence | -39 | -8 | -213 | -117 |
| Profit for the period | 93 | 111 | 660 | 379 |
| Profit attributable to non-controlling interests | -9 | -10 | -32 | -57 |
| Profit attributable to owners of the parent | 102 | 121 | 692 | 436 |
| Earnings per share (NOK) | 1,02 | 1,22 | 6,95 | 4,38 |
| EBITDA margin | 18,2 % | 19,7 % | 23,6 % | 21,2 % |
| Interim condensed statement of financial position Borregaard Group | |||
|---|---|---|---|
| 31.12. | 30.9. | 31.12. | |
| Amounts in NOK million | 2021 | 2021 | 2020 |
| Assets: | |||
| Intangible assets | 89 | 90 | 86 |
| Property, plant and equipment | 4 191 | 4 052 | 3 973 |
| Right-of-use assets | 351 | 358 | 381 |
| Other assets | 339 | 277 | 380 |
| Investments in joint venture and associate company | 173 | 147 | 38 |
| Non-current assets | 5 143 | 4 924 | 4 858 |
| Inventories | 792 | 799 | 887 |
| Receivables | 1 107 | 1 180 | 1 051 |
| Cash and cash deposits | 124 | 184 | 207 |
| Current assets | 2 023 | 2 163 | 2 145 |
| Total assets | 7 166 | 7 087 | 7 003 |
| Equity and debt: | |||
| Group equity | 4 222 | 4 023 | 3 668 |
| Non-controlling interests | 84 | 92 | 110 |
| Equity | 4 306 | 4 115 | 3 778 |
| Provisions and other liabilities | 257 | 305 | 291 |
| Interest-bearing liabilities | 1 320 | 1 351 | 1 381 |
| Non-current liabilities | 1 577 | 1 656 | 1 672 |
| Interest-bearing liabilities | 224 | 313 | 623 |
| Other current liabilities | 1 059 | 1 003 | 930 |
| Current liabilities | 1 283 | 1 316 | 1 553 |
| Equity and liabilities | 7 166 | 7 087 | 7 003 |
| Equity ratio (%): | 60,1 % | 58,1 % | 53,9 % |
| Interim condensed cash flow statement Borregaard Group Q4 2021 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1.10-31.12 | 1.1-31.12 | ||||||||
| Amounts in NOK million | 2021 | 2020 | 2021 | 2020 | |||||
| Profit before taxes | 132 | 119 | 873 | 496 | |||||
| Amortisation, depreciation and impairment charges | 107 | 113 | 420 | 449 | |||||
| Change in net working capital, etc | 174 | 200 | 256 | -21 | |||||
| Dividend/share of profit from JV & associates | 6 | -12 | 6 | 51 | |||||
| Taxes paid | -63 | -4 | -124 | -89 | |||||
| Cash flow from operating activities | 356 | 416 | 1 431 | 886 | |||||
| Investments property, plant and equipment and intangible assets * | -262 | -191 | -701 | -503 | |||||
| Other capital transactions | 4 | 12 | 9 | 14 | |||||
| Cash flow from Investing activities | -258 | -179 | -692 | -489 | |||||
| Dividends | 0 | 0 | -249 | -229 | |||||
| Proceeds from exercise of options/shares to employees | 4 | 1 | 59 | 35 | |||||
| Buy-back of shares | -7 | -1 | -118 | -62 | |||||
| Gain/(loss) on hedges for net investments in subsidiaries | -25 | 59 | -14 | 10 | |||||
| Net paid to/from shareholders | -28 | 59 | -322 | -246 | |||||
| Proceeds from interest-bearing liabilities | 0 | 200 | 300 | 1 550 | |||||
| Repayment of interest-bearing liabilities | -146 | -257 | -814 | -1 703 | |||||
| Change in interest-bearing receivables/other liabilities | 4 | -12 | -1 | 18 | |||||
| Change in net interest-bearing liablities | -142 | -69 | -515 | -135 | |||||
| Cash flow from financing activities | -170 | -10 | -837 | -381 | |||||
| Change in cash and cash equivalents | -72 | 227 | -98 | 16 | |||||
| Cash and cash equivalents at beginning of period | 76 | -127 | 96 | 81 | |||||
| Change in cash and cash equivalents | -72 | 227 | -98 | 16 | |||||
| Currency effects cash and cash equivalents | 1 | -4 | 7 | -1 | |||||
| Cash and cash equivalents at the end of the period | 5 | 96 | 5 | 96 | |||||
| * Investment by category: | |||||||||
| Replacement investments | 190 | 153 | 398 | 344 | |||||
| Expansion investments | 72 | 38 | 303 | 159 |
| Operating revenues | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.1-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.1 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | |
| Amounts in NOK million | 2017 | 2018 | 2019 | 2019 | 2019 | 2019 | 2019 | 2020 | 2020 | 2020 | 2020 | 2020 | 2021 | 2021 | 2021 | 2021 | 2021 |
| Borregaard | 4 618 | 4 785 | 1 250 | 1 340 | 1 239 | 1 234 | 5 063 | 1 372 | 1 358 | 1 260 | 1 338 | 5 328 | 1 419 | 1 511 | 1 429 | 1 446 | 5 805 |
| BioSolutions | 2 594 | 2 775 | 755 | 781 | 720 | 726 | 2 982 | 797 | 819 | 733 | 733 | 3 082 | 812 | 885 | 838 | 934 | 3 469 |
| BioMaterials | 1 672 | 1 661 | 394 | 472 | 430 | 416 | 1 712 | 454 | 417 | 403 | 458 | 1 732 | 523 | 482 | 468 | 405 | 1 878 |
| Fine Chemicals | 370 | 374 | 110 | 96 | 96 | 104 | 406 | 128 | 131 | 131 | 153 | 543 | 90 | 155 | 132 | 114 | 491 |
| Eliminations | - 18 | - 25 | - 9 | - 9 | - 7 | - 12 | - 37 | -7 | -9 | -7 | -6 | -29 | -6 | -11 | -9 | -7 | -33 |
| EBITDA | |||||||||||||||||
| 1.1-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.1 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | |
| Amounts in NOK million | 2017 | 2018 | 2019 | 2019 | 2019 | 2019 | 2019 | 2020 | 2020 | 2020 | 2020 | 2020 | 2021 | 2021 | 2021 | 2021 | 2021 |
| Borregaard | 1 055 | 903 | 255 | 283 | 286 | 183 | 1 007 | 242 | 361 | 266 | 263 | 1 132 | 302 | 416 | 391 | 263 | 1 372 |
| BioSolutions | 545 | 499 | 168 | 192 | 156 | 131 | 647 | 170 | 193 | 132 | 137 | 632 | 205 | 272 | 251 | 214 | 942 |
| BioMaterials | 414 | 312 | 45 | 64 | 94 | 31 | 234 | 46 | 101 | 91 | 80 | 318 | 64 | 102 | 91 | 27 | 284 |
| Fine Chemicals | 96 | 92 | 42 | 27 | 36 | 21 | 126 | 26 | 67 | 43 | 46 | 182 | 33 | 42 | 49 | 22 | 146 |
| Depreciations and write downs | |||||||||||||||||
| 1.1-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.1 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | |
| Amounts in NOK million | 2017 | 2018 | 2019 | 2019 | 2019 | 2019 | 2019 | 2020 | 2020 | 2020 | 2020 | 2020 | 2021 | 2021 | 2021 | 2021 | 2021 |
| Borregaard | - 306 | - 323 | - 98 | - 104 | - 106 | - 110 | - 418 | -109 | -112 | -112 | -110 | -443 | -106 | -101 | -103 | -106 | -416 |
| BioSolutions | - 94 | - 113 | - 41 | - 44 | - 48 | - 50 | - 183 | -51 | -51 | -53 | -51 | -206 | -48 | -45 | -47 | -49 | -189 |
| BioMaterials | - 192 | - 189 | - 49 | - 53 | - 50 | - 51 | - 203 | -50 | -52 | -51 | -50 | -203 | -50 | -47 | -47 | -49 | -193 |
| Fine Chemicals | - 20 | - 21 | - 8 | - 7 | - 8 | - 9 | - 32 | -8 | -9 | -8 | -9 | -34 | -8 | -9 | -9 | -8 | -34 |
| Amortisation | |||||||||||||||||
| 1.1-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.1 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | |
| Amounts in NOK million | 2017 | 2018 | 2019 | 2019 | 2019 | 2019 | 2019 | 2020 | 2020 | 2020 | 2020 | 2020 | 2021 | 2021 | 2021 | 2021 | 2021 |
| Borregaard | - 4 | - 4 | - 1 | - 1 | - 1 | - 1 | - 4 | -1 | -1 | -1 | -2 | -5 | -1 | -1 | -1 | -1 | -4 |
| BioSolutions | - 4 | - 4 | - 1 | - 1 | - 1 | - 1 | - 4 | -1 | -1 | -1 | -2 | -5 | -1 | -1 | -1 | -1 | -4 |
| BioMaterials | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fine Chemicals | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other income and expenses | |||||||||||||||||
| 1.1-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.1 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | |
| Amounts in NOK million | 2017 | 2018 | 2019 | 2019 | 2019 | 2019 | 2019 | 2020 | 2020 | 2020 | 2020 | 2020 | 2021 | 2021 | 2021 | 2021 | 2021 |
| Borregaard | -9 | 0 | 0 | -16 | 0 | -11 | -27 | 0 | -96 | 0 | -20 | -116 | 0 | 0 | 0 | 0 | 0 |
| BioSolutions | 0 | 0 | |||||||||||||||
| -9 | 0 | 0 | -16 | 0 | 0 | -16 | 0 | -90 | 0 | -7 | -97 | 0 | 0 | 0 | |||
| BioMaterials | 0 | 0 | 0 | 0 | 0 | -11 | -11 | 0 | -6 | 0 | -12 | -18 | 0 | 0 | 0 | 0 | 0 |
| Fine Chemicals | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | -1 | 0 | 0 | 0 | 0 | 0 |
| Operating profit (EBIT) | |||||||||||||||||
| 1.1-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.1 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | |
| Amounts in NOK million | 2017 | 2018 | 2019 | 2019 | 2019 | 2019 | 2019 | 2020 | 2020 | 2020 | 2020 | 2020 | 2021 | 2021 | 2021 | 2021 | 2021 |
| Borregaard | 736 | 576 | 156 | 162 | 179 | 61 | 558 | 132 | 152 | 153 | 131 | 568 | 195 | 314 | 287 | 156 | 952 |
| BioSolutions | 438 | 382 | 126 | 131 | 107 | 80 | 444 | 118 | 51 | 78 | 77 | 324 | 156 | 226 | 203 | 164 | 749 |
| BioMaterials Fine Chemicals |
222 76 |
123 71 |
- 4 34 |
11 20 |
44 28 |
- 31 12 |
20 94 |
-4 18 |
43 58 |
40 35 |
18 36 |
97 147 |
14 25 |
55 33 |
44 40 |
-22 14 |
91 112 |
| Quarterly segment information Borregaard Group | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hedging effects & currency exposure | |||||||||||||||||
| 1.1-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.1 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | |
| Amounts in NOK million | 2017 | 2018 | 2019 | 2019 | 2019 | 2019 | 2019 | 2020 | 2020 | 2020 | 2020 | 2020 | 2021 | 2021 | 2021 | 2021 | 2021 |
| Borregaard - EBITDA hedging gains & losses | -72 | -11 | -8 | -13 | -23 | -32 | -76 | -62 | -84 | -51 | -44 | -241 | -15 | -4 | -16 | 6 | -29 |
| BioSolutions | -22 | 3 | -4 | -6 | -9 | -14 | -33 | -26 | -38 | -21 | -18 | -103 | -5 | -1 | -6 | 1 | -11 |
| BioMaterials | -36 | -3 | -3 | -7 | -11 | -16 | -37 | -30 | -39 | -25 | -22 | -116 | -8 | -3 | -8 | 4 | -15 |
| Fine Chemicals | -14 | -11 | -1 | 0 | -3 | -2 | -6 | -6 | -7 | -5 | -4 | -22 | -2 | 0 | -2 | 1 | -3 |
| Borregaard - USD EBITDA currency exposure (approx) Borregaard - EUR EBITDA currency exposure (approx) |
207 84 |
194 84 |
203 98 |
177 112 |
198 139 |
||||||||||||
| Sales revenues | |||||||||||||||||
| 1.1-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.1 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | |
| Amounts in NOK million | 2017 | 2018 | 2019 | 2019 | 2019 | 2019 | 2019 | 2020 | 2020 | 2020 | 2020 | 2020 | 2021 | 2021 | 2021 | 2021 | 2021 |
| Borregaard | 4 522 | 4 705 | 1 222 | 1 311 | 1 214 | 1 204 | 4 951 | 1 347 | 1 337 | 1 229 | 1 314 | 5 227 | 1 394 | 1 491 | 1 406 | 1 424 | 5 715 |
| BioSolutions | 2 524 | 2 708 | 728 | 753 | 697 | 695 | 2 873 | 775 | 800 | 706 | 714 | 2 995 | 793 | 865 | 819 | 915 | 3 392 |
| BioMaterials | 1 634 | 1 630 | 385 | 465 | 422 | 407 | 1 679 | 445 | 407 | 395 | 448 | 1 695 | 513 | 472 | 457 | 398 | 1 840 |
| Fine Chemicals | 365 | 369 | 109 | 94 | 95 | 102 | 400 | 127 | 130 | 128 | 153 | 538 | 88 | 154 | 131 | 112 | 485 |
| Eliminations | - 1 | - 2 | 0 | - 1 | 0 | 0 | - 1 | 0 | 0 | 0 | -1 | -1 | 0 | 0 | -1 | -1 | -2 |
| BioSolutions | |||||||||||||||||
| 1.1-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.1 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | |
| 2017 | 2018 | 2019 | 2019 | 2019 | 2019 | 2019 | 2020 | 2020 | 2020 | 2020 | 2020 | 2021 | 2021 | 2021 | 2021 | 2021 | |
| Average gross sales price NOK per mtds | 5 618 | 5 654 | 6 385 | 5 999 | 5 865 | 6 455 | 6 166 | 6 885 | 7 431 | 6 701 | 6 756 | 6 951 | 7 838 | 7 709 | 7 761 | 9 244 | 8 106 |
| Volume (`000 mtds) | 450 | 468 | 115 | 125 | 119 | 111 | 470 | 115 | 106 | 99 | 96 | 416 | 90 | 100 | 92 | 84 | 366 |
| Specialities volume (`000 mtds) | 83 | 86 | 86 | 88 | 89 | ||||||||||||
| Contruction volume (`000 mtds) | 210 | 212 | 209 | 178 | 131 | ||||||||||||
| Industrial volume (`000 mtds) | 157 | 170 | 175 | 150 | 146 | ||||||||||||
| BioMaterials | |||||||||||||||||
| 1.1-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.1 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | |
| 2017 | 2018 | 2019 | 2019 | 2019 | 2019 | 2019 | 2020 | 2020 | 2020 | 2020 | 2020 | 2021 | 2021 | 2021 | 2021 | 2021 | |
| Average gross sales price NOK per mt | 10 589 | 10 337 | 10 724 | 10 561 | 10 982 | 10 417 | 10 665 | 11 382 | 12 579 | 11 780 | 11 128 | 11 678 | 10 641 | 10 754 | 10 972 | 10 911 | 10 807 |
| Volume (`000 mt) | 150,7 | 150,1 | 34,5 | 42,4 | 37,6 | 38,6 | 153,1 | 40,0 | 33,9 | 34,2 | 40,3 | 148,4 | 47,5 | 42,4 | 40,2 | 34,3 | 164,4 |
| High specialised as % of total cellulose product sales volum | 72 % | 62 % | 73 % | 77 % | 79 % | ||||||||||||
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.